Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 631-639

  Molino, Caroline de Godoi Rezende Costa ^a   Carnevale, Renata Cavalcanti ^a   Rodrigues, Aline Teotonio ^a   Visacri, Marília Berlofa ^a   Moriel, Patricia ^a   Mazzola, Priscila Gava ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

AIDS; Clinical pharmacy; HIV; Pharmaceutical care; pharmacy service

Indexed keywords

ADULT; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL CARE; OUTPATIENT; PHARMACIST; PHARMACIST INTERVENTION; PROSPECTIVE STUDY; UNIVERSITY HOSPITAL; VIRUS LOAD;

EID: 84924266664     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S61821     Document Type: Article

References (43)

1. Martin S, Wolters PL, Calabrese SK, et al. The Antiretroviral Regimen Complexity Index. A novel method of quantifying regimen complexity. J Acquir Immune Defic Syndr. 2007;45(5):535-544.
2. Anderson AM, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. Curr HIV/AIDS Rep. 2006;3(2):79-85.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
4. Ministry of Health and Health Surveillance Secretariat (Brazil). National STD/AIDS Programme. Recommendations on Antiretroviral Therapy in HIV-infected Adults and Adolescents. Final rules. Fed Regist. 2012: 37-57. Available from: http://www.aids.gov.br/sites/default/files/anexos/ publicacao/2012/52140/consenso_adulto2012_principais_mudancas_pdf_11946.pdf. Accessed July 24, 2014.
5. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11.
6. Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence. 2012;6:297-322.
7. Mok S, Minson Q. Drug-related problems in hospitalized patients with HIV infection. Am J Health Syst Pharm. 2008;65(1):55-59.
8. de Maat MM, de Boer A, Koks CH, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther. 2004;29(2):121-130.
9. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drugrelated problems: their structure and function. DICP. 1990;24(11): 1093-1097.
10. Nunes P, Pereira B, Nominato J, et al. [Pharmaceutical intervention and prevention of drug related problems]. Braz J Pharm Sci. 2008;44(4): 691-699. Portuguese.
11. Okie S. Fighting HIV-lessons from Brazil. N Engl J Med. 2006; 354(19):1977-1981.
12. Brazil, Ministry of Health. Aids No Brasil. Departamento de DST, AIDS e Hepatites Virais/SVS/MS; 2012. Avaliable from: http://www. aids.gov.br/sites/default/files/anexos/page/2010/36364/aids_no_ brasil_2012_17137.pdf. Accessed April 30, 2013.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines For the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2013. Avaliable from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 27, 2013.
14. Neogi U, Heylen E, Shet A, et al. Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. PLoS One. 2013;8(1):e55421.
15. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care. 2010;22(10):1189-1194.
16. Heelon M, Skiest D, Tereso G, et al. Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients. Am J Health Syst Pharm. 2007;64(19):2064-2068.
17. de Lyra DP, Kheir N, Abriata JP, da Rocha CE, Dos Santos CB, Pelá IR. Impact of pharmaceutical care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil. Ther Clin Risk Manag. 2007;3(6):989-998.
18. Blix HS, Viktil KK, Moger TA, Reikvam A. Characteristics of drugrelated problems discussed by hospital pharmacists in multidisciplinary teams. Pharm World Sci. 2006;28(3):152-158.
19. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-964.
20. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and metaanalyses. Med Care. 2010;48(10):923-933.
21. Ivama AM, Noblat L, de Castro MS, et al. Consenso Brasileiro de Atenção Farmacêutica: Proposta. Organização Pan Americana da Saúde [Brazilian Consensus of Pharmaceutical Care: Proposal. Pan American Health Organization (OPAS)]; 2002. Available from: http:// bvsms.saude.gov.br/bvs/publicacoes/PropostaConsensoAtenfar.pdf. Accessed April 30, 2013.
22. Pereira L, de Freitas O. The evolution of pharmaceutical care and the prospect for Brazil. Braz J Pharm Sci. 2008;44(4):601-612. Portuguese.
23. Zhu M, Guo DH, Liu GY, et al. Exploration of clinical pharmacist management system and working model in China. Pharm World Sci. 2010;32(4):411-415.
24. King RC, Fomundam HN. Remodeling pharmaceutical care in SubSaharan Africa (SSA) amidst human resources challenges and the HIV/ AIDS pandemic. Int J Health Plann Manage. 2010;25(1):30-48.
25. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging. 2008;3(3):453-472.
26. Hasse B, Ledergerber B, Furrer H, et al; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-1139.
27. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8(3):e59551.
28. Friis-Møller N, Sabin CA, Weber R, et al; Data Collection on Averse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
29. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31(6):1467-1475.
30. Crum-Cianflone N, Roediger MP, Eberly L, et al; Infectious Disease Clinical Research Program HIV Working Group. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106.
31. Cipolle RJ, Strand L, Morley PC. Pharmaceutical Care Practice: The Clinician's Guide. 2nd ed. New York, NY: McGraw-Hill; 2004.
32. Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102(3):275-280.
33. Geletko SM, Poulakos MN. Pharmaceutical services in an HIV clinic. Am J Health Syst Pharm. 2002;59(8):709-713.
34. Rastegar DA, Knight AM, Monolakis JS. Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis. 2006;43(7):933-938.
35. Carcelero E, Tuset M, Martin M, et al. Evaluation of antiretroviralrelated errors and interventions by the clinical pharmacist in hospitalized HIV-infected patients. HIV Med. 2011;12(8):494-499.
36. Viktil KK, Blix HS, Moger TA, Reikvam A. Interview of patients by pharmacists contributes significantly to the identification of drugrelated problems (DRPs). Pharmacoepidemiol Drug Saf. 2006;15(9): 667-674.
37. Pastakia SD, Corbett AH, Raasch RH, Napravnik S, Correll TA. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. Ann Pharmacother. 2008;42(4):491-497.
38. Binquet C, Chêne G, Jacqmin-Gadda H, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol. 2001;153(4):386-393.
39. March K, Mak M, Louie SG. Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm. 2007;64(24):2574-2578.
40. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15(2):185-194.
41. Pádua CA, César CC, Bonolo PF, Acurcio FA, Guimarães MD. High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res. 2006;39(4):495-505.
42. Morillo Verdugo R, Gil Navarro MV, Abdel-Kader Martín L, Castillo Muñoz A, Baños Roldán U, Artacho Criado S. [Analysis of the causes and predictive factors for discontinuing treatment with tenofovir in pretreated HIV patients]. Farm Hosp. 2007;31(4):200-205. Spanish.
43. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17(3):213-223.